Objective: Regulatory T cells (Tregs) contribute to HIV-1 disease progression by impairing antiviral immunity; however, the precise mechanisms responsible for the development of Tregs in the setting of HIV-1 infection are incompletely understood.
Introduction
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that are generated because of aberrant myelopoiesis under certain pathological conditions, such as cancer, inflammatory, and infectious diseases [1] [2] [3] . MDSCs suppress immune responses via increased expression of inflammatory and immunosuppressive mediators, including inducible nitric oxide synthase, arginase 1, reactive oxygen species, IL-4 receptor-a (IL-4Ra), programmed death-ligand 1 (PD-L1), IL-10, tumor growth factor-b (TGF-b), and phosphorylated signal transducer and activator of transcription 3 (pSTAT-3), all of which are important mediators of innate immune responses against pathogenic infections [4] [5] [6] [7] [8] [9] [10] . In mice, MDSCs are defined by the coexpression of the Gr-1 and CD11b surface antigens; whereas human MDSCs are less well characterized because of the lack of uniform phenotypic markers. However, they usually express the common myeloid markers CD33 and CD11b, but lack the maturation marker human leukocyte antigen -antigen D related (HLA-DR [7] [8] [9] [10] . Given the heterogeneous nature of MDSCs, human MDSCs are primarily dissected into two subsets: monocytic MDSCs (M-MDSCs; CD33 þ CD11b þ CD14 þ HLA-DR low/À ) and granulocytic MDSCs (G-MDSCs; CD33 þ CD11b þ CD14 À HLA-DR low/À ). These two subtypes of MDSCs can have different biological functions and use different mechanisms for immune suppression [1] [2] [3] .
Although the immunosuppressive roles of MDSCs have been well characterized in many tumor models, their roles during infectious diseases have been less well studied, in particular during responses to retroviral infections that cause immunodeficiency. Although MDSCs can contribute to immune homeostasis after infection by limiting excessive inflammatory processes, their expansion may be at the expense of pathogen elimination and thus may lead to infection persistence or latency. Recent studies report MDSC expansion plays a role in suppressing T-cell responses and disease progression of HIV-1 infection [11] [12] [13] [14] [15] [16] [17] [18] . However, the phenotypic and functional features of MDSCs and their mechanisms in regulation of T-cell responses in HIV-1 seropositive (HIV-1 þ ) individuals remain unclear. This is particularly true for those on antiretroviral therapy (ART) with undetectable viremia, as they exhibit persistent dampened immunity, such as lower expression of T helper 1 (Th1) cytokines and poor response to vaccinations [19] . Thus, phenotypic and functional characterizations of MDSCs in ART-controlled HIV-infected individuals may delineate the mechanisms by which MDSCs mediate immunosuppression and promote viral persistence or latency.
In this study, we characterized MDSCs in HIV-1 þ individuals on ART with undetectable viremia and determined whether MDSCs contribute to the induction or maintenance of regulatory T (Treg) cell development and suppression of T-effector (Teff) cell function during latent HIV-1 infection. We provide evidence that HIV-induced MDSCs control T-cell differentiation and functions, which represents a novel mechanism for viral persistence and a new strategy for immunotherapy against human viral diseases.
Methods

Participants
The study protocol was approved by the joint institutional review board at East Tennessee State University and James H. Quillen VA Medical Center (ETSU/VA IRB, Johnson City, Tennessee). The study participants were composed of two populations: 65 chronically HIV-1 infected individuals and 72 healthy participants. In this study, we focused on HIV-1 patients who are on ART (truvada-based regimen) with undetectable viremia (aviremia, HIV RNA < 20 copies/ml) and CD4 þ cell count ranging from 220 to 1250. Healthy participants were negative for hepatitis B virus, hepatitis C virus, and HIV infection and blood buffy coats were obtained from Key Biologics, LLC (Memphis, Tennessee, USA) or Physician's Plasma Alliance LLC (Gray, Tennessee, USA). Written informed consent was obtained from all participants.
Peripheral blood mononuclear cell preparation and analysis by flow cytometry
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by Ficoll-Percoll gradients centrifugation (GE Heathcare, Piscataway, New Jersey, USA). For phenotypic analysis of MDSCs, PBMCs were immune stained with CD14-PerCP710, CD11bphycoerythrin (PE) CD33-APC (eBioscience, San Diego, California, USA), and HLA-DR-fluorescin isothiocyanate (FITC) (BD Bioscience, San Jose, California) antibodies or isotype controls. The cells were collected on an Accuri C6 flow cytometer (BD, Franklin Lakes, New Jersey, USA) and analyzed using FlowJo software (Tree Star, Inc., Ashland, Oregon, USA). For intracellular cytokine staining, PBMCs were stimulated with 1 mg/ml lipopolysaccharides (LPS) (Santa Cruz Biotechnology, Santa Cruz, California, USA) plus 2.5 mg/ml R848 (Santa Cruz) for 6 h, and 1 mg/ml Brefeldin A (BioLegend, San Diego, California, USA) was added 5 h prior to harvest. The cells were fixed and permeabilized using Inside Stain Kit (Miltenyi Biotec, Auburn, California, USA), and then stained with IL-10-PE, TGF-b-PE, PD-L1(CD274)-PE (BD Bioscience), IL-4Ra-PE (R&D, Minneapolis, Minnesota, USA), p47 phox , and rat antimouse IgG1-PE. For pSTAT3-PE (pY705) staining, PBMCs were processed with Fix Buffer I and Perm Buffer III (BD) following the BD Phosflow protocol. The cells were also stained with surface antigens CD14-PerCP710, CD33-APC (clone p67.6), and HLA-DR-FITC, then analyzed by flow cytometry. The fluorescence minus one strategy and isotype controls were used to adjust multicolor compensation for cell gating and determine background levels.
Treatment of healthy peripheral blood mononuclear cells by HIV-1 proteins, lipopolysaccharides, and/or STA-21 PBMCs from study participants were treated with HIV-1 gp120, Tat, b-gal (2 mg/ml, ViroGen), or LPS (1 mg/ml, Santa Cruz), in the presence or absence of specific pSTAT-3 inhibitor STA-21 or dimethyl sulfoxide (DMSO) control (20 mmol/l, Santa Cruz). The cells were harvested at different time points for staining with CD33-APC, HLA-DR-FITC, CD11b-PE, and CD14-PerCP710, or isotype controls, followed by flow cytometric analysis.
Regulatory T-cell induction CD33 þ HLA-DR À and CD33 À HLA-DR À were isolated from PBMCs of HIV-1 þ individuals by first selection of HLA-DRpopulations, followed by positive selection of CD33 þ cells using their microbeads according to the manufacturer's instructions (Miltenyi Biotec., cell purity >95%). The purified immature myeloid cells or nonmyeloid cells from HIV-1 þ individuals were cocultured with healthy CD4 þ T cells, or autologous HIV-1 CD4 þ T cells, respectively, in a ratio of 1 : 2 in the presence of 1 mg/ml anti-CD3 and 2 mg/ml anti-CD28 (BD Bioscience) for 3 days. Treg cell differentiation were analyzed by flow cytometry after staining with CD4-PE, CD25-Alexa488, Foxp3-PE-Cy5 (eBioscience), or isotype controls, using Foxp3 Staining Buffer Set (Milenyi Biotec).
T-effector cell cytokine assays
PBMCs from HIV þ individuals, with or without depletion of CD33 þ myeloid cells using CD33 microbeads (Miltenyi Biotec), were stimulated with 1 mg/ml anti-CD3 and 2 mg/ml anti-CD28 for 72 h. The cells were treated with 1 mg/ml Brefeldin A for 5 h before harvest. Teff intracellular cytokine expressions were assessed by IFNg-PE (BD Bioscience) or isotype, control staining, followed by flow cytometry analysis as described above.
Statistical analysis
The data were summarized as mean AE SEM or median with interquartile range, depending on the characteristics of the data distribution. Comparisons among groups were made by one-way analysis of variance or Kruskal-Wallis test, followed with Dunn's or Fisher's multiple comparisons test. Independent t test or paired t test was used to compare the difference of mean between each two groups. Mann-Whitney test or Wilcoxon signed rank test was used to compare the difference of median between each two groups. All the data were analyzed using Minitab 17.0 and Graphpad Prism v6.0. Ã P < 0.05, or ÃÃ P < 0.01, and ÃÃÃ P < 0.001 were considered significant or very significant, respectively.
Results
Monocytic myeloid-derived suppressor cells are expanded in HIV-1 R individuals on antiretroviral therapy Phenotypically, human MDSCs express the common myeloid markers CD33 and CD11b, but lack the maturation marker HLA-DR [7] [8] [9] [10] . As an initial approach to determine the role of MDSCs in the pathogenesis of HIV-1 persistence and latency, we first compared the frequency of MDSCs in the peripheral blood of 31 HIV-1 þ individuals on ART with undetectable viremia and 22 healthy participants. As shown in Fig. 1 , the representative dot plots of flow cytometry and summary data for the frequencies of different myeloid cell populations, PBMCs were first gated on CD11b þ and CD33 þ myeloid cells, and then analyzed for the immature HLA-DR low/À populations within the monocytic (CD14 þ ) and granulocytic (CD14 À ) subsets ( Fig. 1a ). Although the overall numbers of myeloid cells (CD33 þ CD11b þ ) in HIV-1 þ individuals were slightly lower than those in healthy participants ( Fig. 1b ), the numbers of MDSCs (HLA-DR low/ À CD33 þ CD11b þ ) ( Fig. 1c ), in particular the M-MDSC (CD14 þ HLA-DR low/À CD33 þ CD11b þ ) subset ( Fig. 1d ), but not the G-MDSC (CD14 À HLA-DR low/ À CD3 þ CD11b þ ) subset ( Fig. 1e ), were significantly higher in HIV-1 þ individuals. These results indicate that latently HIV-infected patients on ART have elevated numbers of M-MDSCs in their peripheral blood, consistent with the reports of MDSC expansion in actively HIV-infected individuals [11] [12] [13] [14] [15] [16] [17] [18] . Although it has been reported that the elevated M-MDSC frequency in HIV-1 viremic patients correlated with prognostic disease markers, including the HIV-1 RNA level, CD4 þ T-cell number, and activated T cells [13] , we did not find such a correlation of MDSC and CD4 þ cell frequencies in these HIV-1 aviremic participants on ART. These data are the first observation showing that HIV-1 þ individuals on ART with undetectable viremia still exhibit expanded M-MDSCs.
Immunosuppressive proteins are increased in monocytic myeloid-derived suppressor cells from HIV-1 R individuals MDSCs are more accurately identified by their immunosuppressive functions rather than their phenotypic markers. MDSCs exert their suppressive activities via expression or secretion of copious amounts of immunosuppressive mediators [4] [5] [6] [7] [8] [9] [10] . For example, IL-4Ra, also known as CD124, is a 140 kDa transmembrane glycoprotein that binds IL-4 and IL-13, which are primarily responsible for IL-4-dependent activation of transcription factors that induce Th2 cell expansion [20] . PD-L1, also known as CD274 or B7-H1, is a 40 kDa transmembrane protein that has been speculated to play a major role in suppressing the host immune system during inflammation or infection [21] . P47 phox is a 47 kDa cytosolic subunit of the multiprotein complex NADPH oxidase that is responsible for respiratory burst of phagocytes during defense responses [22] . IL-10 and TGF-b are known to regulate immune responses via phosphorylation of STAT-3 (pSTAT-3) [23] . To functionally characterize MDSCs during HIV-1 infection, we measured these inhibitory proteins and regulatory cytokines that have been suggested to play a role in MDSC expansion or suppressive functions [4] [5] [6] [7] [8] [9] [10] . As shown in Fig. 2a , the representative dot plots of flow cytometry, and Fig. 2b -g, summary data for the expression of different cell mediators in M-MDSCs, including IL-4Ra, PD-L1, p47 phox , IL-10, TGF-b, and pSTAT-3, all these inhibitory mediators expressed in M-MDSCs were found to be significantly upregulated in PBMCs from HIV-1 þ individuals compared with healthy participants, suggesting that these molecules are involved in the differentiation and/or suppressive functions of MDSCs during viral infection.
HIV-1 proteins (gp120 and Tat) prevent myeloid cell maturation and drive myeloid-derived suppressor cell expansion
Despite several reports of increases in the numbers of MDSCs in HIV-1 þ individuals, factors responsible for MDSC expansion during HIV-1 infection are unclear. As patients with chronic HIV-1 infection often suffer from confounding factors that may drive MDSC expansion, we determined whether the increased numbers of MDSCs during HIV-1 infection were directly caused by HIV-1 or other factors. To this end, purified PBMCs from healthy participants were incubated with recombinant HIV-1 gp120 or Tat, two important proteins that have been shown to exert immunomodulatory effects [14, [24] [25] [26] , or the control protein b-gal for different times, followed by the analysis of myeloid cell differentiation and maturation with flow cytometry. As shown in Fig. 3a , the representative dot plots of flow cytometry, and Fig. 3b-d , summary data for the frequencies of different myeloid cell populations by days after the treatment, healthy PBMCs treated with HIV-1 gp120 or Tat protein exhibited a slightly lower number of CD33 þ CD11b þ myeloid cells (data not shown), but a relatively higher number of CD14 þ cells and HLA-DR low/À cells, when 1524 AIDS 2016, Vol 30 No 10 compared with those treated with the control protein, leading to an increased CD14 þ HLA-DR low/À subsets in the CD11b þ CD33 þ myeloid cell populations after the treatment (Fig. 3b ). Overall, an increased M-MDSCs in PBMCs was observed ( Fig. 3c ), significantly higher at day 4-5 after gp120 or Tat treatment (three-dimensional), when compared with those exposed to the control protein. Notably, the frequencies of M-MDSCs decreased following PBMC incubation with the control protein, which is contributed by the decreased expression of CD14 but increased expression of HLA-DR maturation marker, indicating myeloid cell differentiation into a mature status when cultured in vitro over a period of time; whereas the CD14 þ HLA-DR low/À population of myeloid cells remain in an immature state after exposure to HIV-1 proteins. These findings, which are in line with the observations in HIV-infected patients vs. healthy participants in vivo ( Fig. 1b and e ), suggest that HIV-1 derived proteins prevent myeloid cell maturation and drive them toward differentiation into M-MDSCs.
HIV-1 protein (gp120) induces myeloid-derived suppressor cell development via the signal transducer and activator of transcription-3 pathway STAT-3 phosphorylation and activation has been shown to play a pivotal role in myelopoiesis [27] [28] [29] . To further study the role of STAT-3 signaling in HIV-1-induced expansion of M-MDSCs, we incubated healthy PBMCs with HIV-1 gp120 or control b-gal protein with or without the pSTAT-3-specific inhibitor STA-21 [30] for 5 days, followed by flow cytometric analysis. As shown in Fig. 4a , the representative dot plots of flow cytometry and Fig. 4b and c, summary data for the frequencies of pSTAT-3 expression and M-MDSC development following the treatment, healthy PBMCs treated with HIV-1 gp120 exhibited a significantly higher number of pSTAT-3 þ M-MDSCs compared with those exposed to the control protein. This in-vitro result is in line with the findings in vivo that HIV-1 þ individuals exhibit significantly higher numbers of pSTAT-3 þ M-MDSCs compared to the healthy participants (Fig. 2g ). In addition, the HIV-1 gp120-induced M-MDSC expansion could be abrogated by pSTAT-3 inhibitor when compared with those cells treated with DMSO control. Of note, STA-21 treatment alone did not affect the M-MDSC development. Overall, these data suggest that HIV-1 gp120 induces M-MDSC differentiation via the STAT-3 pathway.
HIV particular for patients on ARTwith undetectable viremia ( Fig. 1) . Recent reports suggest that ART-controlled, HIV-1 þ individuals exhibit a chronic inflammatory state with overactivation of the immune system and T-cell exhaustion during latent viral infection, which can be promoted by multiple inflammatory mediators, including Toll-like receptor (TLR) ligands such as LPS [31] [32] [33] [34] . In addition, we have recently observed, in a gene array analysis, that TLR4 was upregulated on CD33 þ myeloid cells derived from HIV-1 þ individuals as well as HCVinfected individuals vs. healthy participants (data not show), suggesting that TLR4 pathway may be involved in MDSC expansion during viral infections. To determine whether TLR4 stimulation can cause MDSC development through the STAT-3 pathway, we incubated healthy PBMCs with or without LPS in the presence of pSTAT-3 inhibitor STA-21 or DMSO for 5 days, followed by flow cytometric analysis for the MDSC development. As shown in Fig. 4d , PBMCs treated with LPS in vitro resulted in a significant increase in CD33 þ HLA-DR low/À MDSCs, and these LPS-induced MDSC increases could be abrogated by the presence of pSTAT-3 inhibitor STA-21 when compared with the DMSO control. Of note, monocytic marker CD14 expression was almost lost on the surface of myeloid cells when they were cultured in vitro for 5 days, whereas LPS treatment prevented CD14 loss and HLA-DR expression, resulting in an inhibition of myeloid cell maturation and increase in M-MDSC numbers (Fig. 4e) . Again, these LPS-induced M-MDSCs were diminished by the presence of STAT-3 inhibitor. Taken together, these results indicate that, in addition to HIV-1 proteins, LPS/TLR4-mediated inflammatory response can also induce MDSC development via the STAT-3 pathway. 
Myeloid-derived suppressor cells promote regulatory T-cell development during HIV-1 infection
In addition to producing inhibitory proteins, it has been suggested that MDSCs exert their immunosuppressive functions by inducing CD4 þ CD25 þ Foxp3 þ Treg cell differentiation in cancer patients and organ transplant recipients [35] [36] [37] . Therefore, we next sought to determine whether HIV-induced MDSCs can induce Foxp3 þ Treg development. To this end, we first incubated healthy CD4 þ T cells with or without MDSCs derived from HIV þ individuals for 3 days, followed by flow cytometric analysis for the differentiation of CD25 þ Foxp3 þ Treg cells. As shown in Fig. 5a , the representative dot plots of flow cytometry and summary data for the coculture experiments, healthy CD4 þ T cells cocultured with CD33 þ myeloid cells isolated from HIV þ individuals induced a significant increase in Foxp3 þ Tregs when compared with healthy CD4 þ T cells incubated alone without the presence of HIV CD33 þ myeloid cells. Given the heterogeneous populations of MDSCs, we further tested the role of MDSCs in induction of Tregs by coculturing healthy CD4 þ T cells with or without HIV immature myeloid cells (CD33 þ HLA-DR À ). In this case, we use HIV immature nonmyeloid cells (CD33 À HLA-DR À ), in addition to the healthy participants CD4 þ T cells cultured alone, as controls. As shown in Fig. 5b , healthy CD4 þ T cells cocultured with CD33 þ HLA-DR À cells derived from HIV þ individuals induced a significant increase in Foxp3 þ Tregs when compared with those cocultured with HIV immature nonmyeloid control cells (CD33 À HLA-DR À ), or healthy CD4 þ T cells incubated alone (baseline). As accumulation of Tregs is a characteristic of many chronic infectious diseases, including latent HIV-1 infection on ART [38, 39] , we also examined whether MDSCs are essential for maintaining the Foxp3 þ Treg cells in the cultured conditions. To this end, we incubated HIV CD4 þ T cells with or without autologous MDSCs ex vivo for 3 days, followed by flow cytometric analysis for the frequencies of Foxp3 þ Tregs. As shown in Fig. 5c , purified HIV CD4 þ T cells incubated alone without the presence of HIV CD33 þ HLR-DR À MDSCs resulted in a significant decrease in Foxp3 þ Treg cells when compared with those cultured with HIV CD33 þ HLA-DR À MDSCs. In addition, HIV CD4 þ T cells cocultured with HIV immature nonmyeloid cells (CD33 À HLA-DR À , MDSC depleted) also resulted in a significant decrease in the Foxp3 þ Treg cells when compared with those cocultured with HIV immature myeloid cells (CD33 þ HLA-DR À ). Taken together, these results indicate that 
Myeloid-derived suppressor cells inhibit IFNg production by T-effector cells during HIV-1 infection
In addition to inducing Treg cell development, we also studied whether MDSCs from HIV þ individuals can directly or indirectly inhibit Teff cell functions by depletion experiments. To this end, PBMCs from HIV-1 þ individuals were depleted for CD33 þ myeloid cells (enrich in MDSCs), stimulated by anti-CD3 and anti-CD28 for 3 days, followed by flow cytometric analysis for IFNg production by CD4 þ T cells. As shown in Fig. 5d , the representative overlaid histogram of flow cytometry and summary data for the IFNg production by CD4 þ T cells, compared with the cultures of bulk PBMCs, depletion of CD33 þ myeloid cells from PBMCs derived from HIV þ individuals resulted in a significant increase of IFNg production by CD4 þ T cells. This holds true by measuring both the percentage of IFNg expressing CD4 þ T-cell frequencies and the mean fluorescence intensity of the IFNg expression levels in CD4 þ T cells. Overall, these results indicate that HIV-mediated MDSCs can inhibit Teff cell functions.
Discussion
As the discovery of MDSCs, there has been rapid progress in the understanding of this particular type of suppressor cells in tumor progression and antitumor response. However, the role of MDSCs in viral persistence or latency remains controversial and far from clear. For example, although some studies have shown that monocytic MDSCs are remarkably elevated and play a role in the pathogenesis of HIV or HCV infection [13] [14] [15] [40] [41] [42] , Bowers et al. [16] reported an immune suppression by neutrophils during HIV-1 infection; whereas Nonnenmann et al. [43] found no significant increases in MDSCs and lack of their suppressive functions in peripheral blood of chronically HCVinfected individuals. We postulated that these discrepancies in MDSC frequency and suppressive capability might partially result from measuring different MDSC subsets, using different methodologies, investigating different patient populations, and/or focusing on different disease stages with specific cytokine milieus that may induce distinct MDSC phenotypes. In this study, we observed substantial increases in the monocytic (CD14 þ ) immature (HLA-DR low/À ) myeloid cells (CD33 þ CD11b þ ) in latently HIV-1-infected patients on ART with undetectable viremia. These M-MDSCs, expressing significantly high levels of IL-4Ra, PD-L1, P47 phox , IL-10, TGF-b, and pSTAT-3, could induce Foxp3 þ Treg cell expansion and inhibit IFNg production by CD4 þ Teff cells, which may play a pivotal role in the chronicity of HIV-1 infection.
The mechanism underlying MDSC expansion in virusinfected individuals remains unclear. It has been suggested that the generation of MDSCs can be induced by the virus itself or by its coding proteins, including HCV, HIV, and lymphocytic choriomeningitis virus [13] [14] [15] [40] [41] [42] 44] . For example, Garg and Spector [14] reported that HIV gp120-induced MDSC expansion is dependent upon IL-6 signaling. Here, we demonstrated that HIV-1 gp120 can induce M-MDSC expansion via the STAT-3 pathway, which is closely related to IL-6 signaling. Although HIV-1 or its proteins may induce MDSC development in the active or early phase of viral infection, the mediators involved in induction or maintenance of MDSC development in the latent phase of viral infection have not been identified, in particular for patients well controlled by effective ART, which is our targeted population in this study. Notably, MDSCs expand in nearly all conditions where inflammation exists [1] [2] [3] , and compelling data have shown that latently HIV-infected individuals, despite being well controlled by ART and exhibiting unmeasurable viral RNA or proteins, still exhibit a dampened immunity, as evidenced by low expression of Th1 cytokines and poor response to vaccinations [19] . These latently HIV-infected patients exhibit a chronic inflammatory state with immune cells overactivation followed by exhaustion or anergy and/or premature T-cell aging or senescence; a series of detrimental effects that appear to be a major factor in HIV-1 disease progression [31] [32] [33] [34] 45] . Therefore, chronic inflammation or TLR stimulation, as we show LPS-mediated MDSC expansion via the STAT3 pathway in this study, may be the continuing impetus underlying the expansion of MDSCs during the latent phase of HIV-1 infection. These findings underscore the importance of transcription factor STAT-3 in the regulation of MDSC development and suppressive functions, and call for the use of STAT-3 as a potential therapeutic target for infection-associated expansion of MDSCs, during which pSTAT-3 is often induced [26] [27] [28] . Indeed, inhibition of STAT-3 signaling has been shown to directly regulate the production of immunosuppressive cytokines, such as IL-6 and IL-10 [29, 46] .
In summary, this study demonstrates that HIV proteins or inflammatory mediators such as LPS-induced, STAT-3-mediated MDSC expansion contribute to Treg cell development and Teff cell suppression during HIV infection, shedding new light on the features of MDSCs and providing a novel mechanism for T-cell regulation in chronic viral infection. Therefore, targeting MDSCs and/or STAT-3 signaling pathway may be a promising strategy for immunotherapy to treat human viral diseases.
